An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.

导出 OA

翻译打印收藏纠错

作者： Laura,Dumitrescu ^[1] ; Athanasios,Papathanasiou ^[2] ; Catalina,Coclitu ^[3] ; Afagh,Garjani ^[4] ; Nikos,Evangelou ^[5] ; Cris S,Constantinescu ^[3] ; Bogdan Ovidiu,Popescu ^[5] ; Radu,Tanasescu ^[5]

作者单位： Department of Clinical Neurosciences, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania. ^[1] Department of Neurology, Colentina Clinical Hospital, Bucharest, Romania. ^[2] Department of Neurology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK. ^[3] Department of Multiple Sclerosis and Neuroimmunology, CHU Grenoble, Grenoble, France. ^[4] Academic Clinical Neurology, Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK. ^[5] Department of Neurology, Cooper Neurological Institute, Camden, NJ, USA. ^[6]

关键词 Fingolimod multiple sclerosis ozanimod ponesimod siponimod sphingosine 1-phosphate receptor modulators

主题词人类(Humans);多发性硬化(Multiple Sclerosis);疾病大流行(Pandemics);复发(Recurrence)

DOI 10.1080/14656566.2023.2178898

PMID 36946625

发布时间 2023-06-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交